Navigation Links
Researchers discover metabolite linked to aggressive prostate cancer
Date:2/11/2009

AUDIO: Researchers from the University of Michigan Comprehensive Cancer Center have identified a panel of small molecules, or metabolites, that appear to indicate aggressive prostate cancer.

Click here for more information.

ANN ARBOR, Mich. Researchers from the University of Michigan Comprehensive Cancer Center have identified a panel of small molecules, or metabolites, that appear to indicate aggressive prostate cancer.

The finding could lead to a simple test that would help doctors determine which prostate cancers are slow-growing and which require immediate, aggressive treatment.

Results of the study appear in the Feb. 12 issue of Nature.

"One of the biggest challenges we face in prostate cancer is determining if the cancer is aggressive. We end up overtreating our patients because physicians don't know which tumors will be slow-growing. With this research, we have identified a potential marker for the aggressive tumors," says senior study author Arul Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and S.P. Hicks Endowed Professor of Pathology at the U-M Medical School.

The researchers looked at 1,126 metabolites across 262 samples of tissue, blood or urine associated with benign prostate tissue, early stage prostate cancer and advanced, or metastatic, prostate cancer. They mapped the alterations in metabolites and identified about 10 that were present more often in prostate cancer than in the benign cells and were present most often in the advanced cancer samples.

"When we're looking at metabolites, we're looking several steps beyond genes and proteins. It allows us to look very deeply at some of the functions of the cells and the biochemistry that occurs during cancer development," says Chinnaiyan, a Howard Hughes Medical Institute investigator.

One metabolite in particular, sarcosine, appeared to be one of the strongest indicators of advanced disease. Levels of sarcosine, an amino acid, were elevated in 79 percent of the metastatic prostate cancer samples and in 42 percent of the early stage cancer samples. Sarcosine was not found at all in the cancer-free samples.

In the study, sarcosine was a better indicator of advancing disease than the traditional prostate specific antigen, or PSA, test that is currently used to monitor or screen for prostate cancer. Sarcosine was detected in the urine, which has researchers hopeful that a simple urine test could be used.

In addition, the researchers found that sarcosine is involved in the same pathways that are linked to cancer invasiveness. This suggests sarcosine as a potential target for future drug development.

"This research gets at characterizing the chemical complexity of a sample of blood. In the future, this science will drive how doctors make treatment recommendations for their patients," says study author Christopher Beecher, Ph.D., professor of pathology at the U-M Medical School.

Results are preliminary at this point and will need years of further testing and development before this technology would be available for patients.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Researchers Identify Novel Mechanism That Make Cancer Tumors Grow
2. Pathologically elevated blood fat levels in obesity: Researchers discover molecular causes
3. Georgia State researchers shed light on fat burning
4. A better mesh: Researchers tighten bodys protective coating
5. Researchers design re-engineered hospital discharge program to reduce rehospitalization
6. UVA researchers uncover genes role in severity of drinking
7. Johns Hopkins researchers discover new schizophrenia gene
8. Researchers find culture of academic institution may influence health care delivery
9. ISU researchers develop technique for quick detection of Salmonella
10. Study of Iraq veterans traumatic brain injuries to be conducted by UB researchers
11. UT Southwestern researchers identify protein that may explain healthy obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a premium medical cannabis ... the company’s executive management team with prominent executives from both inside and outside the ... Operating Officer, Ted Dumbauld , who has more than twenty years of business ...
(Date:3/29/2017)... ... ... Hamlin Dental Group, multi-location dental office in North Hollywood , Van ... safe and effective options, and can be used alone or in conjunction with other ... care. , Dr. Hamid Reza of Hamlin Dental Group offers other treatments as well, ...
(Date:3/29/2017)... ... March 29, 2017 , ... VisualSP has helped over 1.5 million ... only option for on-premises installation of its Help System for SharePoint was at the ... system into the entire tenant. , The company recently released a modified version ...
(Date:3/28/2017)... SEATTLE, Washington and CARTERSVILLE, Georgia (PRWEB) , ... ... ... adding another senior analyst to its award-winning team. Ruel Williamson brings his extensive ... Advisors, which has been a leader in the real estate valuation industry for ...
(Date:3/28/2017)... ... March 28, 2017 , ... City trips have ... World Travel Trends Report). As travelers visit both urban destinations, they are faced ... prolonged sun exposure. In response, the outdoor industry has blurred the lines between ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017  Glenmark Pharmaceuticals, a global pharmaceutical company, ... investigational fixed-dose combination of mometasone furoate (25 mcg) ... a nasal spray being studied for the treatment ... a recently completed Phase 3 trial assessing the ... versus mometasone, olopatadine or placebo. "We ...
(Date:3/29/2017)... , March 29, 2017  Maxor National Pharmacy ... announced that it has named Leah Bailey ... all divisions of the company. With more ... the previous 8 years focused on health care, Bailey ... her tenure at Prime, Bailey advised the PBM, Specialty, ...
(Date:3/29/2017)... Varian Medical Systems (NYSE: VAR ) ... quarter of fiscal year 2017 following the close of regular ... be followed by a teleconference available to all interested parties ... to the conference call webcast will be available on the ... call and replay: ...
Breaking Medicine Technology: